|Bid||0.00 x 1100|
|Ask||0.58 x 900|
|Day's Range||0.4100 - 0.4300|
|52 Week Range||0.3600 - 1.2200|
|Beta (3Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 7, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.20|
Hunt has more than 25 years of finance and accounting experience excelling as a versatile leader with a successful track record in turnarounds, startups, mergers, divestitures, growth strategies, performance and operations management and analysis at a number of organizations, including Fortune 500 companies. “We are excited to have Jonathan back at IsoRay. Before joining IsoRay, Hunt was Chief Financial Officer at Vivid Learning Systems, where he had a central role in the company’s turnaround, that included growing revenues and implementing financial policy and process changes that ultimately resulted in the successful sale of the company.
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -9.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Richland, Washington-based company said it had a loss of 2 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. In the final minutes of ...
IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2019 ended September 30, 2018 on Thursday, November 8, 2018, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal 2019 after the close of the U.S. stock markets on November 8, 2018.
On a per-share basis, the Richland, Washington-based company said it had a loss of 4 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. For the year, the company ...
Year over year fourth quarter revenues increased 17%Sixth Consecutive Quarter of Year-Over-Year Revenue IncreasesFull year revenues increased 24% RICHLAND, Wash., Sept. 25,.
IsoRay Inc’s (NYSEMKT:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...
The direct benefit for IsoRay Inc (NYSEMKT:ISR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off isRead More...
On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART).
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Both Staffing 360 Solutions and IsoRay were two of the biggest winners in Monday’s trading session with gains of about 300% and 143% respectively. The company, which is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, said it plans to use the net proceeds from this offering for working capital and general corporate purposes with particular focus on marketing the brain applications and Build-Blu™ delivery system for real-time prostate brachytherapy.
Today, IsoRay Inc. (ISR) stock rallied ~160% and closed trading at $1.14, compared to its previous closing price of $0.44. IsoRay’s stock price was triggered by buoyed investor sentiment on the news of the FDA 510(k) clearance for the company’s GammaTile therapy for the treatment of recurrent brain tumors.
LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment ...
IsoRay Inc’s (AMEX:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...
LOS ANGELES, CA / ACCESSWIRE / May 17, 2018 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Tom LaVoy, Chairman of the Board & CEO of IsoRay, Inc. ...
For long term investors, improvement in profitability and outperformance against the industry can be important characteristics in a stock. In this article, I will take a look at IsoRay Inc’sRead More...